The half-reactions are:

Zn(s) + 2OH−(aq) → ZnO(s) + H2O(l) + 2e− 
  
    
      
        
        
      
    
    {\displaystyle \qquad \qquad }
   [E0oxidation = -1.28 V]
2MnO2(s) + H2O(l) + 2e− → Mn2O3(s) + 2OH−(aq)
  
    
      
        
      
    
    {\displaystyle \qquad }
   [E0reduction = +0.15 V]Overall reaction:

Zn(s) + 2MnO2(s) ⇌ ZnO(s) + Mn2O3(s)
  
    
      
        
        
      
    
    {\displaystyle \qquad \qquad }
   [E0total = +1.43 V]The ZnO is prone to clumping and will give less efficient discharge if recharged again. It is possible to recharge these batteries but is due to safety concerns advised against by the manufacturer. Other primary cells include zinc-carbon, zinc-chloride, and lithium iron disulfide batteries. Secondary cell
Contrary to the primary cell a secondary cell can be recharged. The first of which was the lead-acid battery invented in 1859 by French Gaston Planté. This type of battery is still the most widely used in among others automobiles.
In the published study, the overall response rate was 40%, with a median duration of response of 11.1 months, and a median progression-free survival of 8.3 months (95% CI, 6.5 to 10.9).The FDA collaborated on the review of amivantamab with the Brazilian Health Regulatory Agency (ANVISA) and the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA). The application reviews are ongoing at the other regulatory agencies. Society and culture
Legal status
Amivantamab was approved for medical use in the United States in May 2021. On 14 October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Rybrevant, intended for the treatment of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The applicant for this medicinal product is Janssen-Cilag International N.V. Amivantamab was approved for medical use in the European Union in December 2021. Names
Amivantamab is the recommended international nonproprietary name (INN). Research
Amivantamab is being investigated in combination with lazertinib versus osimertinib; and in combination with carboplatin-pemetrexed chemotherapy compared to carboplatin-pemetrexed. References
This article incorporates public domain material from the United States Department of Health and Human Services. Further reading
Neijssen J, Cardoso RM, Chevalier KM, Wiegman L, Valerius T, Anderson GM,  et al. (April 2021). "Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET". J Biol Chem. 296: 100641. doi:10.1016/j.jbc.2021.100641. PMC 8113745. PMID 33839159.